Introduction: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration. Methods: We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration. Results: The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE ε4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage. Discussion: Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design.

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype / Vermunt, L.; Sikkes, S. A. M.; van den Hout, A.; Handels, R.; Bos, I.; van der Flier, W. M.; Kern, S.; Ousset, P. -J.; Maruff, P.; Skoog, I.; Verhey, F. R. J.; Freund-Levi, Y.; Tsolaki, M.; Wallin, A. K.; Olde Rikkert, M.; Soininen, H.; Spiru, L.; Zetterberg, H.; Blennow, K.; Scheltens, P.; Muniz-Terrera, G.; Visser, P. J.; Vellas, B.; Reynish, E.; Ousset, P. J.; Andrieu, S.; Burns, A.; Pasquier, F.; Frisoni, G.; Salmon, E.; Michel, J. P.; Zekry, D. S.; Boada, M.; Dartigues, J. F.; Olde-Rikkert, M. G. M.; Rigaud, A. S.; Winblad, B.; Malick, A.; Sinclair, A.; Frolich, L.; Scheltens, P.; Ribera, C.; Touchon, J.; Robert, P.; Salva, A.; Waldemar, G.; Bullock, R.; Tsolaki, M.; Rodriguez, G.; Spiru, L.; Jones, R. W.; Stiens, G.; Stoppe, G.; Eriksdotter Jonhagen, M.; Cherubini, A.; Lage, P. M.; Gomez-Isla, T.; Camus, V.; Aguera-Morales, E.; Lopez, F.; Savy, S.; Cantet, C.; Coley, N.. - In: ALZHEIMER'S & DEMENTIA. - ISSN 1552-5260. - STAMPA. - 15:7(2019), pp. 888-898. [10.1016/j.jalz.2019.04.001]

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

Cherubini A.;
2019-01-01

Abstract

Introduction: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration. Methods: We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration. Results: The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE ε4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage. Discussion: Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design.
2019
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/330403
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 289
  • ???jsp.display-item.citation.isi??? 267
social impact